title: Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
authors: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
authors: K M
authors: KM
authors: Zunich
authors: H C
authors: HC
authors: Lane
authors: R T
authors: RT
authors: Davey
authors: J
authors: J
authors: Falloon
authors: M
authors: M
authors: Polis
authors: J A
authors: JA
authors: Kovacs
authors: H
authors: H
authors: Masur
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D015686:Gene Products, env / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D016655:HIV Core Protein p24 / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D011498:Protein Precursors / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use / Q000633:toxicity; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D016655:HIV Core Protein p24; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic